Analytical Data
-
Gene name
GNMT
- Application
-
Species
Human
-
Source
E. coli
-
Tag
N-His
-
Purity
Greater than 95% as determined by SDS-PAGE.
-
Uniprot
Q14749
-
Expression Region
Val2~Asp295
-
Molecular Weight
36kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
GNMT (glycine N-methyltransferase) is a vital enzyme involved in the metabolism of glycine and is implicated in various physiological and pathological processes, including amino acid metabolism, one-carbon metabolism, and liver function. The enzyme catalyzes the transfer of a methyl group from S-adenosylmethionine (SAM) to glycine, producing sarcosine and S-adenosylhomocysteine (SAH). Research on GNMT has gained prominence due to its potential role in liver diseases, such as non-alcoholic fatty liver disease (NAFLD) and hepatocellular carcinoma (HCC), where altered GNMT activity may lead to dysregulated methylation processes. Moreover, GNMT is a candidate biomarker for assessing liver health and metabolic disorders. The recombinant expression of GNMT in various systems allows for detailed structural and functional studies, aiding in the understanding of its catalytic mechanisms and regulatory roles. This research is pivotal for designing therapeutic strategies targeting GNMT-related metabolic pathways, potentially leading to novel treatments for liver disorders and metabolic diseases. Overall, the study of GNMT and its recombinant proteins is critical for elucidating its biological significance and harnessing its potential for clinical applications.
